The first stop for professional medicines advice

Biosimilars

25 results

Applied filters

Biosimilar and key generic medicines - delivering better value

7 November 2024An overview of NHS England and NHS SPS roles in implementing biosimilar and key generic medicines and what to expect in 2025/26.

Implementing ustekinumab biosimilar

4 September 2024This webinar provided information and guidance to support organisations switch to the best value ustekinumab biosimilar

Good governance when implementing ustekinumab biosimilar

2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for ustekinumab biosimilars

2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.

Preparing to use ustekinumab biosimilar

16 July 2024Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

Good governance when implementing eculizumab biosimilar

6 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for eculizumab biosimilars

6 March 2024Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.

Preparing to use eculizumab biosimilar

6 March 2024Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

Good governance when implementing tocilizumab biosimilar

5 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for tocilizumab biosimilar

5 March 2024One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.
admin